Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

INTRODUCTION: Ciltacabtagene autoleucel (cilta‐cel) is a novel chimeric antigen receptor T‐cell therapy that is being evaluated in the CARTITUDE‐1 trial (NCT03548207) in patients with relapsed or refractory multiple myeloma (RRMM) who received as part of their previous therapy an immunomodulatory dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Thomas, Krishnan, Amrita, Yong, Kwee, Weisel, Katja, Mehra, Maneesha, Nair, Sandhya, Qi, Keqin, Londhe, Anil, Diels, Joris, Crivera, Concetta, Jackson, Carolyn C., Olyslager, Yunsi, Vogel, Martin, Schecter, Jordan M., Banerjee, Arnob, Valluri, Satish, Usmani, Saad Z., Berdeja, Jesus G., Jagannath, Sundar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematologic Malignancy ‐ Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175662/
https://www.ncbi.nlm.nih.gov/pubmed/35846215
http://dx.doi.org/10.1002/jha2.312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175662/
https://www.ncbi.nlm.nih.gov/pubmed/35846215
http://dx.doi.org/10.1002/jha2.312

Ejemplares similares